Advertisement

Hairy cell leukemia: New understanding of biology and treatment

  • Alan Saven
  • Lawrence D. Piro
  • Carlos J. Carrera
  • Dennis A. Carson
  • Ernest Beutler
Part of the Cancer Treatment and Research book series (CTAR, volume 64)

Abstract

The term Leukemic reticuloendotheliosis, later to be known as hairy cell leukemia (HCL), was first applied by Ewald [1] to a patient with a fulminating, fatal disorder characterized by the circulation of large numbers of abnormal cells in the blood. Although his publication is sometimes cited as the first description of HCL [2], in retrospect it seems more likely that he was actually observing a patient with a form of acute myelogenous leukemia.

Keywords

Clin Oncol Adenosine Deaminase Hairy Cell Leukemia Hairy Cell Purine Nucleoside Phosphorylase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ewald O (1923). Die leukämische reticuloendotheliose. Deutsches Arch Klin Med 142: 222–228.Google Scholar
  2. 2.
    Bouroncle BA, Wiseman BK, Doan CA (1958). Leukemic reticuloendotheliosis. Blood 13: 609–630.PubMedGoogle Scholar
  3. 3.
    Turner A, Kjeldsberg CR (1978). Hairy cell leukemia: A review. Medicine (Bait) 57: 477–499.Google Scholar
  4. 4.
    Schrek R, Donnelly WJ (1966). ‘Hairy’ cells in blood in lymphoreticular neoplastic disease and ‘flagellated’ cells of normal lymph nodes. Blood 27: 199–211.PubMedGoogle Scholar
  5. 5.
    Golomb HM, Catovsky D, Golde DW (1978). Hairy cell leukemia: A clinical review of 71 cases. Ann Intern Med 89: 677–683.PubMedGoogle Scholar
  6. 6.
    Bouroncle BA (1979). Leukemic reticuloendotheliosis (hairy cell leukemia). Blood 53: 412–436.PubMedGoogle Scholar
  7. 7.
    Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU (1984). Alpha-interferon for induction of remission in hairy cell leukemia. N Engl J Med 310: 15–18.PubMedCrossRefGoogle Scholar
  8. 8.
    Spiers ASD, Parekh SJ, Bishop MB (1984). Hairy-cell leukemia: Induction of complete remission with pentostatin (2′-deoxycoformycin). J Clin Oncol 2: 1336–1342.PubMedGoogle Scholar
  9. 9.
    Carson DA, Wasson DB, Beutler E (1984). Anti-leukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc Natl Acad Sci USA 81: 2232–2236.PubMedCrossRefGoogle Scholar
  10. 10.
    Piro LD, Carrera CJ, Beutler E, Carson DA (1988). 2-chlorodeoxyadenosine: An effective new agent for the treatment of chronic lymphocytic leukemia. Blood 72(3): 1069–1073.PubMedGoogle Scholar
  11. 11.
    Piro LD, Miller WE, Carrera CJ, Carson DA, Beutler E (1987). Hairy-cell leukemia. N Engl J Med 317: 901 (letter).CrossRefGoogle Scholar
  12. 12.
    Carrera CJ, Piro LD, Miller WE, Carson DA, Beutler E (1987). Remission induction in hairy cell leukemia by treatment with 2-chlorodeoxyadenosine: Role of DNA strand breaks and NAD depletion. Clin Res 35: 597 A (abstract).Google Scholar
  13. 13.
    Piro LD, Carrera CJ, Carson DA, Beutler E (1990). Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322: 1117–1121.PubMedCrossRefGoogle Scholar
  14. 14.
    Wylis RF, Greene MH, Palretke M, Khilanani P, Tabaczka P, Swiderski G (1982). Hairy cell leukemia in three siblings: An apparent HLA-linked disease. Cancer 49: 538–542.CrossRefGoogle Scholar
  15. 15.
    Wachsman W, Golde DW, Chen IS (1984). Hairy cell leukemia and human T cell leukemia virus. Semin Oncol 11: 446–450.PubMedGoogle Scholar
  16. 16.
    Stewart DJ, Keating MJ (1980). Radiation exposure as a possible etiologic factor in hairy cell leukemia. Cancer 46: 1577–1580.PubMedCrossRefGoogle Scholar
  17. 17.
    Oleske D, Golomb HM, Farber MD, Levy PS (1985). A case-control inquiry into the etiology of hairy cell leukemia. Am J Epidemiol 121: 675–683.PubMedCrossRefGoogle Scholar
  18. 18.
    Anderson KC, Boyd AW, Fisher DC, Leslie D, Schlossman SF, Nadler LF (1985). Hairy cell leukemia: A tumor of pre-plasma cells. Blood 65: 620–629.PubMedGoogle Scholar
  19. 19.
    Hassan IB, Hagberg H, Sundstrom C (1990). Immunophenotype of hairy cell leukemia. Eur J Haematol 45: 172–176.PubMedCrossRefGoogle Scholar
  20. 20.
    Korsmeyer SJ, Greene WC, Cossman J, Hsu SM, Jensen JP, Neckers LM, Marshall SL, Bakhshi A, Depper JM, Leonard WJ, Jaffe ES, Waldmann TA (1983). Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Proc Natl Acad Sci USA 80: 4522.PubMedCrossRefGoogle Scholar
  21. 21.
    Hermann F, Dorken B, Kudwig WD, Schwarting R (1985). A comparison of membrane marker phenotype in hairy-cell leukemia and phorbol ester induced B-CLL using monoclonal antibodies. Leuk Res 9: 529–536.CrossRefGoogle Scholar
  22. 22.
    Steis RG, Marcon L, Clark J, Urba W, Longo DL, Nelson DL, Maluish AE (1988). Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood 77: 1304–1309.Google Scholar
  23. 23.
    Muraguchi A, Kehrl JH, Longo DL (1985). Interleukin-2 receptors on human B cell subpopulations. Implications for the role of interleukin-2 in human B cell function. J Exp Med 162: 181–197.CrossRefGoogle Scholar
  24. 24.
    Cordingly FT, Hoffbrand AV, Heslop HE, Turner M, Bianchi A, Reittie JE, Uyakarnam A, Meager A (1988). Tumor necrosis factor as an autocrine tumor growth factor for B cell malignancies. Lancet i:969–971.CrossRefGoogle Scholar
  25. 25.
    Paganelli KA, Evan SS, Hans T, Ozer H (1986). B cell growth factor-induced proliferation of hairy cell lymphocytes and inhibition by type I interferon in vitro. Blood 67: 937–943.PubMedGoogle Scholar
  26. 26.
    Cimino G, Annino L, Giona F, Sgodani C, DiGregorio AO, Cava MC, Mardelli F (1991). Serum interleukin-1 beta levels correlate with neoplastic bulk in hairy cell leukemia. Leuk Res 3: 602–605.Google Scholar
  27. 27.
    Kipps TJ, Tomhave E, Chen PP, Carson DA (1988). Autoantibody-associated kappa light chain variable region gene expressed in chronic lymphocytic leukemia with little or no somatic mutation. J Exp Med 167: 840–852.PubMedCrossRefGoogle Scholar
  28. 28.
    Mintz U, Golomb HM (1979). Splenectomy as initial therapy in twenty-six patients with leukemic reticuloendotheliosis (hairy cell leukemia). Cancer Res 39: 2366–2370.PubMedGoogle Scholar
  29. 29.
    Golomb HM, Vardiman JW (1983). Response to splenectomy in 65 patients with hairy cell leukemia: An evaluation of spleen weight and bone marrow involvement. Blood 61: 349–352.PubMedGoogle Scholar
  30. 30.
    Jansen J, Hermans J (1981). Splenectomy in hairy cell leukemia: A retrospective multi-center analysis. Cancer 47: 2066–2076.PubMedCrossRefGoogle Scholar
  31. 31.
    Golde DW (1982). Therapy of hairy-cell leukemia. N Engl J Med 307: 495–496.PubMedCrossRefGoogle Scholar
  32. 32.
    Golomb HM, Mintz U (1979). Treatment of hairy cell leukemia (leukemic reticulendo-theliosis). II. Chlorambucil therapy in postsplenectomy patients with progressive disease. Blood 54: 305–309.PubMedGoogle Scholar
  33. 33.
    Golomb HM (1981). Progress report on chlorambucil therapy in postsplenectomy patients with progressive hairy cell leukemia. Blood 57: 464–467.PubMedGoogle Scholar
  34. 34.
    Bertino JR (1979). Hairy cell leukemia (leukemic reticuloendotheliosis): Chemotherapy for splenectomy failures. Blood 54: 297 (editorial).PubMedGoogle Scholar
  35. 35.
    Lusch CJ, Ramsey HE, Katayama I (1978). Leukemic reticuloendotheliosis: Report of a case with peripheral blood remission on androgen therapy. Cancer 41: 1964–1966.PubMedCrossRefGoogle Scholar
  36. 36.
    Blum SF (1983). Lithium in hairy cell leukemia. N Engl J Med 303: 464–465.Google Scholar
  37. 37.
    Orringer EP, Varia MA (1980). A role for radiation in the treatment of hairy cell leukemia complicated by massive lymphadenopathy. A case report. Cancer 45: 2047–2050.Google Scholar
  38. 38.
    Lembersky BC, Ratain MJ, Golomb HM (1988). Skeletal complications in hairy cell leukemia: Diagnosis and therapy. J Clin Oncol 6: 1280–1284.PubMedGoogle Scholar
  39. 39.
    Ratain MJ, Golomb HM, Vardiman JW, Vokes EE, Jacobs RH, Daly K (1985). Treatment of hairy cell leukemia with recombinant alpha-2 interferon. J Clin Oncol 65:P644–648.Google Scholar
  40. 40.
    Jacobs AD, Champlin RE, Golde DW (1985). Recombinant alpha-2 interferon for hairy cell leukemia. J Clin Oncol 65: 1017–1020.Google Scholar
  41. 41.
    Golomb HM, Jacobs A, Fefer A, Ozer H, Thompson J, Portlock C, Ratain M, Golde D, Vardiman J, Burke JS, Brady J, Bonnern E, Spiegel R (1986). Alpha-2 interferon therapy of hairy cell leukemia: A multicenter study of 64 patients. J Clin Oncol 4: 900–905.PubMedGoogle Scholar
  42. 42.
    Golomb HM, Fefer A, Golde DW, Ozer H, Portlock C, Silber R, Rappeport J, Ratain MJ, Thompson J, Bonnern EM, Spiegel RJ, Tensen L, Burke JS, Vardiman JW (1987). Sequential evaluation of alpha-2b interferon treatment in 128 patients with hairy cell leukemia. Semin Oncol 14(Suppl 2): 13–17.PubMedGoogle Scholar
  43. 43.
    Golomb HM, Fefer A, Golde DW, Ozer H, Portlock C, Silber R, Rappeport J, Ratain MJ, Thompson J, Bonnern E, Spiegel R, Tensen L, Burke JS, Vardiman JW (1988). Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon alfa-2b. Semin Oncol 14(Suppl 5):7–9.Google Scholar
  44. 44.
    Golomb H, Fefer A, Golde D, Ozer H, Portlock C, Silber R, Rappeport J, Ratain M, Thompson J, Bonnern E, Spiegel R, Tensen L, Burke J, Vardiman J (1990). Update of a multi-institutional study of 195 patients (pts) with hairy cell leukemia (HCL) treated with interferon alfa-2b (IFN). Proc Am Soc Clin Oncol 6: 215.Google Scholar
  45. 45.
    Golomb HM, Ratain MJ, Fefer A, Thompson J, Golde DW, Ozer H, Portlock C, Silber R, Rappeport J, Bonnern E, Spiegel R, Tensen L, Burke JS, Vardiman JW (1988). Randomized study of the duration of treatment with interferon alfa-2b in patients with hairy cell leukemia. J Natl Cancer Inst 80: 369–373.PubMedCrossRefGoogle Scholar
  46. 46.
    Berman E, Heller G, Kempin S, Gee T, Tran L, Clarkson B (1990). Incidence of response and long-term follow-up in patients with hairy cell leukemia with recombinant alpha-2a. Blood 75: 839–845.PubMedGoogle Scholar
  47. 47.
    Quesada JR, Hersh EM, Manning J, Reuben J, Keating M, Schnipper E, Itri L, Gutterman JU (1986). Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood 68: 493–497.PubMedGoogle Scholar
  48. 48.
    Foon KA, Maluish AE, Abrams PG, Wrightington S, Stevenson HC, Alarif A, Fer MF, Overton WR, Poole M, Schnipper EF, Jaffe ES, Herberman RB (1986). Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Therapeutic and immunologie results. Am J Med 80: 351–356.PubMedCrossRefGoogle Scholar
  49. 49.
    Glaspy JA, Marcus SG, Ambersley J, Golde DW (1989). Recombinant beta-serine-interferon in hairy cell leukemia compared prospectively with results with recombinant alpha-interferon. Cancer 64: 409–413.PubMedCrossRefGoogle Scholar
  50. 50.
    Dutcher JP, Salva KM, Wiernik P (1990). Successful treatment of hairy cell leukemia with 2′-deoxycoformycin after failure of interferon alpha or beta. Am J Clin Oncol 13: 290–293.PubMedCrossRefGoogle Scholar
  51. 51.
    Quesada JR, Alexanian R, Kurzrock R, Barlogie B, Saks S, Gutterman JU (1988). Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenstrom’s macroglobulinemia. Am J Hematol 29: 1–4.PubMedCrossRefGoogle Scholar
  52. 52.
    Davidson HS, Schilsky RL, Golomb HM (1985). Gonadal and sexual function following treatment of hairy cell leukemia with recombinant alpha-2 interferon. Proc Am Soc Clin Oncol 4: 232.Google Scholar
  53. 53.
    Schilsky RL, Davidson HS, Magid D, Daiter S, Golomb HM (1987). Gonadal and sexual function in male patients with hairy cell leukemia: Lack of adverse effects of recombinant alpha 2-interferon treatment. Cancer Treat Rep 71(2): 179.PubMedGoogle Scholar
  54. 54.
    Ruco LP, Procapio A, Maccallini V, Calogero A, Uccini S, Annino L, Mandelli F, Baroni CD (1983). Severe deficiency of natural killer activity in the peripheral blood of patients with hairy cell leukemia. Blood 61: 1132.PubMedGoogle Scholar
  55. 55.
    Lee SH, Kelley S, Chin H, Stebbing N (1982). Stimulation of natural killer cell activity and inhibition of proliferation of various leukemic cells by purified human leukocyte interferon subtypes. Cancer Res 42: 1312.PubMedGoogle Scholar
  56. 56.
    Taylor-Papadimitriou J (1980). Effects of interferons on cell growth and function. In Interferon 1980, Vol. 2, Gresser I (ed). Academic Press: New York, pp. 13–46.Google Scholar
  57. 57.
    Lieberman D, Voloch Z, Aviv H, Nudel U, Revel M (1974). Effects of interferon on hemoglobin synthesis and leukemia virus production in Friend cells. Mol Biol Rep 1: 447–451.PubMedCrossRefGoogle Scholar
  58. 58.
    Carson DA, Carrera CJ (1990). Immunodeficiency secondary to adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. Semin Hematol 27: 260–269.PubMedGoogle Scholar
  59. 59.
    Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA (1985). Mechanism of deoxy-adenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 75: 377–383.PubMedCrossRefGoogle Scholar
  60. 60.
    Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, Carson DA (in press). Relationship of deoxycytidine kinase and cyto-plasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993.Google Scholar
  61. 61.
    Steis RG, Urba WJ, Kopp WC, Alvord WG, Smith JW, Longo DL (1991). Kinetics of recovery of CD4+ cells in peripheral blood of deoxycoformycin-treated patients. J Natl Cancer Inst 83: 1578–1679.CrossRefGoogle Scholar
  62. 62.
    Urba WJ, Baseler MW, Kopp WC, Steis RG, Clark JW, Smith JW II, Coggin DL, Longo DL (1989). Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia. Blood 73: 38–46.PubMedGoogle Scholar
  63. 63.
    Kraut EH, Neff JC, Bouroncle BA, Gochnour D, Grever MR (1990). Immunosuppressive effects of pentostatin. J Clin Oncol 8: 848–855.PubMedGoogle Scholar
  64. 64.
    Carrera CJ, Piro LD, Saven A, Cox K, Beutler E, Carson DA, Kipps TJ (1990). Restoration of lymphocyte subsets following 2-chlorodeoxyadenosine remission induction in hairy cell leukemia. Blood 76(Suppl 1):260a.Google Scholar
  65. 65.
    Spiers ASD, Parekh SJ (1983). Pentostatin (2′-deoxycoformycin, DCF) is active in hairy cell leukemia (HCL). Blood 62: 208.Google Scholar
  66. 66.
    Spiers ASD, De Conti RC, Parekh SJ, Ramnes CR, Oken MM (1986). Hairy cell leukemia (HCL): pentostatin (dcF, 2′-deoxycoformycin) as primary therapy and after failure of splenectomy and alpha-interferon (IFN). Proc Am Soc Clin Oncol 5: 151.Google Scholar
  67. 67.
    Kraut ED, Bouroncle BA, Grever MR (1986). Low-dose deoxycoformycin in the treatment of hairy cell leukemia. Blood 68: 1119–1122.PubMedGoogle Scholar
  68. 68.
    Kraut EH, Bouroncle BA, Grever MR (1989). Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 7: 168–172.PubMedGoogle Scholar
  69. 69.
    Spiers ASD, Moore D, Cassileth PA, Harrington DP, Cummings FJ, Neiman RS, Bennett JM, O’Connell MJ (1987). Remissions in hairy-cell leukemia with pentostatin (2′-deoxycoformycin). N Engl J Med 316: 825–871.PubMedCrossRefGoogle Scholar
  70. 70.
    Cassileth PA, Cheuvant B, Spiers ASD, Harrington DP, Cummings FJ, Neiman RS, Bennett JM, O’Connell MJ (1991). Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol 9: 243–246.PubMedGoogle Scholar
  71. 71.
    Ho AD, Thaler J, Mandelli F, Lauria F, Zittoun R, Willemze R, McVie G, Marmont AM, Prummer O, Stryckmans P, Witt B, Suciu S, Solbu G, de Witte T, Bödewadt-Radzun S (1989). Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. J Clin Oncol 7: 1533–1538.PubMedGoogle Scholar
  72. 72.
    Sorensen JM, Chun HG, Vena D, Fallavollita A, Cheson BD (1991). Pentostatin (DCF) therapy for hairy cell leukemia (HCL): Update of a Group C protocol of 208 patients (pts) who have failed interferon-alpha (IFNa). Proc Am Soc Clin Oncol 10: 232.Google Scholar
  73. 73.
    O’Dwyer PJ, Cheson BD, Leyland-Jones B, King SA, Hoth DF (1988). Deoxycoformycin: An active new drug for indolent lymphomas and hairy cell leukemia. Oncology 2: 17–22.PubMedGoogle Scholar
  74. 74.
    Foon KA, Nakano GM, Koller CA, Longo DL, Steis RG (1986). Response to 2′-deoxycoformycin after failure of interferon-α in nonsplenectomized patients with hairy cell leukemia. Blood 68: 297–300.PubMedGoogle Scholar
  75. 75.
    Johnston JB, Glazer RI, Pugh L, Israels LG (1986). The treatment of hairy-cell leukemia with 2′-deoxycoformycin. Br J Haematol 63: 525–534.PubMedCrossRefGoogle Scholar
  76. 76.
    Carson DA, Wasson DB, Beutler E (1981). Antileukemia and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc Natl Acad Sci USA 81: 2232–2236.CrossRefGoogle Scholar
  77. 77.
    Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD (1991). 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk. Lymphoma 5 (Suppl):133–138.CrossRefGoogle Scholar
  78. 78.
    Beutler E, Piro LD, Saven A, Kay AC, McMillan R, Longmire RL, Carrera CJ, Carson DA (1991). 2-Chlorodeoxyadenosine (2-CdA): A potent chemotherapeutic and immunosuppressive nucleotide. Leuk. Lymphoma 5: 1–8.CrossRefGoogle Scholar
  79. 79.
    Kay AC, Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD (1992). 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 10: 371–377.PubMedGoogle Scholar
  80. 80.
    Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD (1992). 2-Chlorodeoxyadenosine: An active agent in the treatment of cutaneous T-cell lymphoma. Blood 80: 587–592.PubMedGoogle Scholar
  81. 81.
    Piro LD, Carrera CJ, Carson DA, Beutler E (1990). Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322: 1117–1121.PubMedCrossRefGoogle Scholar
  82. 82.
    Piro LD, Saven A, Ellison D, Thurston D, Carson DA, Beutler E (1992). Prolonged complete remissions following 2-chlorodeoxyadenosine (2-CdA) in hairy cell leukemia (HCL). Proc Am Soc Clin Oncol 11: 846.Google Scholar
  83. 83.
    Hoffman M, Rai K, Sawitsky A, Janson D (1991). 2-chlorodeoxyadenosine (2-CdA) in hairy cell leukemia. Blood 78(Suppl 1):454a (abstract).Google Scholar
  84. 84.
    Estey EM, Kurzrock R, Kantarjian HM, O’Brien S, McCredie K, Beran M, Koller C, Keating M, Hirsch-Ginsberg C, Huy YO, Stass S, Freireich E (1992). Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 79: 882–887.PubMedGoogle Scholar
  85. 85.
    Juliusson G, Liliemark J (1992). Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′-deoxyadenosine (CdA): Relation to opportunistic infections. Blood 79: 888–894.PubMedGoogle Scholar
  86. 86.
    Tallman M, Hakimian D, Variakojis D, Kaul K, Koslow D (1991). 2-Chlorodeoxyadenosine (2-CdA) in the treatment of hairy cell leukemia (HCL). Blood 78(Suppl 1):34a (abstract).Google Scholar
  87. 87.
    Lauria F, Benfenati D, Zinzani PL, Raspadori D, Rondelli D, Tura S (1991). 2-Chloro-deoxyadenosine in the treatment of hairy cell leukemia patients relapsed after a-interferon. Blood 78(Suppl 1):34a (abstract).Google Scholar
  88. 88.
    Kantarjian HM, Schachner J, Keating MJ (1991). Fludarabine therapy in hairy cell leukemia. Cancer 67: 1291–1293.PubMedCrossRefGoogle Scholar
  89. 89.
    Kantarjian HM, Redman J, Keating MJ (1990). Fludarabine phosphate therapy in other lymphoid malignancies. Semin Oncol 17(Suppl 8):66–70.PubMedGoogle Scholar
  90. 90.
    Glaspy JA, Baldwin GC, Robertson PA, Souza L, Vincent M, Ambersley J, Golde DW (1988). Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Ann Intern Med 109: 789–795.PubMedGoogle Scholar
  91. 91.
    Glaspy J, Ambersley J, Narachi M, Wyres M, Golde D (1990). Treatment of hairy cell leukemia (HCL) with granulocyte colony stimulating factor (G-CSF) and alpha interferon (IFN-a). Proc Am Soc Clin Oncol 9: 213.Google Scholar
  92. 92.
    Grever M, Kopecky K, Head D, et al. (1992). A randomized comparison of deoxycoformycin (DCF) versus alpha-2a interferon (IFN) in previously untreated patients with hairy cell leukemia (HCL): An NCI-sponsored Intergroup Study (SWOG, ECOG, CALGB, NCIC, CTG). Proc Am Soc Clin Oncol 11: 868 (abstract).Google Scholar
  93. 93.
    Nerenstone S, Martin A, Urba W, Lawrence J, Clark J, Smith J, Crum E, Miller R, Schoenberger C, Hawkins M, Longo D, Steis R (1988). Treatment of hairy cell leukemia (HCL) with alternating cycles of 2′ deoxycoformycin (DCF) and recombinant alpha-2a interferon (IFN). Proc Am Soc Clin Oncol 7: 176.Google Scholar
  94. 94.
    Martin A, Nerenstone S, Urba W, Longo DL, Lawrence JB, Clark JW, Hawkins MJ, Creekmore SP, Smith JW II, Steis RG (1990). Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: Results of a Phase II study. J Clin Oncol 4: 721–730.Google Scholar
  95. 95.
    Habermann T, Vangeneugden T, Cassileth P, Bennett J, Andersen J, Oken M (1990). A phase II trial for the evaluation of recombinant alpha-2A interferon (Roferon-AR) followed by 2′ deoxycoformycin (pentostatin) (dCF) in the therapy of hairy cell leukemia in previously splenectomized patients. Proc Am Soc Clin Oncol 9: 211.Google Scholar
  96. 96.
    Carrera CJ, Cottam HB, Wasson B, Kipps TJ, Saven A, Piro LD, Beutler E, Carson DA (1992). Stability and oral activity of 2-chloro-2′ara-fluoro-2′-deoxyadenosine (CAFdA) in a SCID mouse model of chronic lymphocytic leukemia (CLL). Proc Am Soc Clin Oncol 11: 268 (abstract).Google Scholar
  97. 97.
    Rai K, Mick R, Ozer H, Silver R, Papish S, Bloomfield C (1987). Alpha-interferon therapy in untreated active hairy cell leukemia: A Cancer and Leukemia Group B (GALGB) study. Proc Am Soc Clin Oncol 6: 159.Google Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Alan Saven
  • Lawrence D. Piro
  • Carlos J. Carrera
  • Dennis A. Carson
  • Ernest Beutler

There are no affiliations available

Personalised recommendations